In 2022, 22 states and the District of Columbia reported clinical cases of Candida auris, a fungus deemed an urgent public health threat due to its resistance to multiple antifungal treatments.
Clinical cases are those in which infection is present, compared to screening cases, which refer to cases where the fungus is detected and has colonized but has not led to infection.
Health agencies consider C. auris among the pathogens that pose the greatest threat to public health because of its ability to spread quickly in healthcare settings and cause severe infections among immunocompromised people. The U.S. saw its first clinical case in 2016. Between 2020 and 2021, cases grew 95%. Read more about C. auris here.
Below is a list of the number of clinical cases reported in the U.S. in 2022, based on CDC data. A total of 2,377 cases were reported in 22 states and Washington, D.C:
Nevada: 384 clinical cases
California: 359
Florida: 349
New York: 326
Illinois: 276
Texas: 160
New Jersey: 94
Indiana: 87
Ohio: 79
Maryland: 46
Virginia: 40
Michigan: 33
Pennsylvania: 33
Kentucky: 22
District of Columbia: 19
Arizona: 17
Georgia: 12
Louisiana: 10
Tennessee: 8
Alabama: 6
Delaware: 5
Mississippi: 5
Massachusetts: 2
Colorado: 1
Hawaii: 1
Minnesota: 1
New Mexico: 1
Wisconsin: 1